Exchange: NASDAQ·Updated 07:51 PM EDT

BMEA News

News
all
press releases
Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data
Biomea Fusion stock falls after ending a public securities offering and revising clinical data timelines for its obesity trial.read more...
Benzinga
Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data
Biomea Fusion stock falls after ending a public securities offering and revising clinical data timelines for its obesity trial.read more...
Benzinga
More News
Biomea Fusion Shares Fall 19% After Hours: Here's Why
Biomea Fusion shares fall nearly 19% after hours, highlighting volatility in BMEA after Tuesday's session.read more...
Benzinga
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Zacks
Are Medical Stocks Lagging Brookdale Senior Living (BKD) This Year?
Here is how Brookdale Senior Living (BKD) and Biomea Fusion, Inc. (BMEA) have performed compared to their sector so far this year.
Zacks
Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion
Shares of Biomea Fusion are trading sharply higher on Monday following an operational milestone for its lead metabolic drug program.read more...
Benzinga
Biomea Fusion Status Update: Experts Discuss Icovamenib's Promise Ahead of ADA 2026
Rodman & Renshaw Director of Research Michael King hosted an endocrinology-focused discussion with Dr. Alexander Abitbol, an endocrinologist and assistant medical director at LMC Healthcare, ahead of the American Diabetes Association (ADA) meeting in New Orleans. The conversation centered on tre...
MarketBeat
Biomea Fusion (NASDAQ:BMEA) Coverage Initiated by Analysts at Citizens Jmp
Citizens Jmp began coverage on shares of Biomea Fusion in a research note on Tuesday. They issued a 'market outperform' rating and a $9.00 target price on the stock...
MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of "Moderate Buy" from Analysts
Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings...
MarketBeat
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib
Biomea Fusion (NASDAQ:BMEA) executives highlighted early, exploratory clinical data for icovamenib in type 1 diabetes, presenting top-line results from the company's COVALENT-112 proof-of-concept...
MarketBeat
Biomea Fusion (NASDAQ:BMEA) Given Buy Rating at D. Boral Capital
D. Boral Capital reissued a "buy" rating and issued a $12.00 price objective on shares of Biomea Fusion in a research report on Tuesday...
MarketBeat

Advertisement|Remove ads.